Mesenchymal precursor cell

• US 7,670,628 B2
• Filed: 03/29/2004
• Issued: 03/02/2010
• Est. Priority Date: 07/07/1999
• Status: Expired due to Term

• Current Assignee: Mesoblast, Inc. (Mesoblast Ltd.)
• Original Assignee: Angioblast Systems, Inc.
• Inventors: Gronthos, Stan, Zannettino, Andrew, Simmons, Paul
• Primary Examiner(s): Belyavskyi; Michail A
• Application Number:
  US10/813,747
• Publication Number:
  US 20050019911A1
• Time in Patent Office: 2,164 Days
• Field of Search: None
• US Class Current: 424/577
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: C12N 2500/42 Organic phosphate, e.g. beta glycerophosphate
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2506/1353 from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0691 Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels

Abstract

A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.

Claims

1. A method of generating bone tissue in a subject comprising administering to the subject a population of cells enriched for STRO-1^bright cells, or culture expanded colony-forming-unit-fibroblasts (CFU-Fs) derived therefrom, wherein such STRO-1^bright cells are mesenchymal precursor cells capable of giving rise to CFU-Fs, so as to generate bone tissue in the subject.

2. The method of claim 1, wherein the mesenchymal precursor cells carry at least one additional marker selected from the group of surface markers consisting of THY-1, VCAM-1, STRO-2, and CD146.

3. The method of claim 2, wherein the mesenchymal precursor cells carry the markers STRO-1 and VCAM-1.

4. The method of claim 1, wherein the STRO-1^bright cells are negative for at least one marker selected from the group consisting of CBFA-1, collagen type II, PPARγ

2, and glycophorin A.